Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply174
Issue Information120
AP&T: Editors' Declarations of Interest109
Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification93
Issue Information91
86
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC84
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease81
Development of a model to identify patients who do not need oesophageal biopsies when eosinophilic oesophagitis is suspected75
Systematic Review: Variability in Definitions of Fibrostenosis in Eosinophilic Oesophagitis74
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply71
Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease67
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?67
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation67
Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients65
Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment65
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease63
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply62
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?57
55
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis51
Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies51
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep50
Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases50
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis49
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis49
Issue Information49
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease47
47
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC46
Editorial: The future of managing drug induced liver injury46
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted46
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply45
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply45
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B45
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply45
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough44
Editorial: Plants against animals44
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply43
Letter: Ozanimod and latent tuberculosis43
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply43
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease43
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply43
0.1129150390625